Summit Therapeutics’ (SMMT) Operational Momentum Sparks Market Interest

Summit Therapeutics Inc. (NASDAQ: SMMT) announced its financial and operational developments before to the start of trading on Wednesday, which caused a significant spike in the company’s stock on the US stock charts. SMMT shares had a noteworthy 19.59% increase during normal trading hours, ending at $4.70.

Summit Therapeutics (SMMT) unveiled its financial outcomes and provided insights into its operational strides for the initial quarter concluded on March 31, 2024. The company’s operational journey persists with ivonescimab (SMT112), an investigative, potentially pioneering bispecific antibody that amalgamates immunotherapy’s PD-1 blockade effects with the anti-angiogenesis properties associated with VEGF inhibition into a single molecular entity.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything. According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.


January 2024 marked the one-year milestone of Summit Therapeutics’ Collaboration and License Agreement closure with Akeso Inc. for ivonescimab (SMT112), which has seen over 1,600 subjects enrolled in clinical trials globally. Summit Therapeutics secured rights for ivonescimab’s development and commercialization in the United States, Canada, Europe, and Japan, while Akeso retains these rights for the rest of the globe, including China.

Following the acquisition of ivonescimab, SMMT initiated late-stage clinical endeavors in non-small cell lung cancer (NSCLC) and is actively enrolling participants in two pivotal Phase III trials. In January 2024, subsequent to a presentation at ELCC 2024 in March 2024, Akeso disclosed updates derived from its Phase II AK112-201 trial data.

In April 2024, an esteemed addition graced the boardroom of Summit Therapeutics as Mostafa Ronaghi, PhD, assumed a directorial role. Dr. Ronaghi, renowned as a co-founder of Cellanome and a stalwart member of its executive echelon, brings a wealth of expertise to the table.

His tenure as Chief Technology Officer at Illumina, Inc. spanning from 2008 to 2021 underscored his pivotal role in steering the company’s technological trajectory. Notably, Dr. Ronaghi’s visionary contributions in 2016 culminated in the inception of GRAIL, a groundbreaking innovation in cancer diagnostics via liquid biopsy.

Most Popular

Related Posts